Through a Glass Darkly: Economics and Personalised Medicine

PharmacoEconomics

Volumn 32, Issue 11, 2014, Pages 1055-1061

  Haycox, Alan ^a   Pirmohamed, Munir ^a   McLeod, Claire ^a   Houten, Rachel ^a   Richards, Sarah ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; DRUG INDUSTRY; ECONOMIC EVALUATION; GENETIC SCREENING; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRESCRIPTION; RISK BENEFIT ANALYSIS; ECONOMICS; GENETICS;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DISCOVERY; HUMANS; PHARMACOGENETICS; PRECISION MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84911006269     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0190-6     Document Type: Article

References (25)

1. Becla L, Lunshof J, Gurwitz D, et al. Health technology assessment in the era of personalized medicine. Int Jn Tech Ass Health Care. 2011;27:118–26
2. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92:467–75.
3. Fleeman N, Dundar Y, Dickson R, et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J. 2011;11:1–14.
4. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003;192:23–32.
5. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8:283–9.
6. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329:15–9.
7. Miller I, Ashton-Chess J, Fert V, et al. Market access challenges in the EU for high medical value diagnostic tests. Personal Med. 2011;8:137–48.
8. Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalised patients: a meta-analysis of prospective studies. JAMA. 1998;279:1200–5.
9. Mertens G. Beyond the blcokbuster drug. Business insights. 2005. Available from http://www.pharmatree.in/pdf/reports/Beyond%20the%20Blockbuster%20Drug_Strategies%20for%20nichebuster%20drugs,%20targeted%20therapies%20and%20personalized%20medicine.pdf.
10. Roden D, Wilke R, Kroemer H, Stein M. Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011;123(15):1661–70.
11. Chalkidou K, Rawlins M. Pharmacogenetics and cost-effectiveness analysis: a two-way street. Drug Discov Today. 2011;16:873–7.
12. Trushheim MR, Berndt ER. Economic challenges and possible policy actions to advance stratified medicine. Personalized Med. 2012;9(4):413–27.
13. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.
14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.
15. Di Nicolantonio F, Arena S, Gallicchio M, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci. 2008;105:20864–9.
16. Campbell B. How to judge the value of innovation: More evidence is needed but promise; is important early on. BMJ. 2012;344:e1457.
17. NICE. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat. Available from http://www.nice.org.uk/nicemedia/live/13283/62767/62767.pdf.
18. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116:496–526.
19. Kraus WE, Haga SB, McLeod HL, et al. Conference scene: is personalized medicine ready for prime time. Personalized Med. 2012;9(5):475–8.
20. Fleeman N, McLeod C, Bagust A, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. 2010;14(3):1–157.
21. Fleeman N, Martin Saborido C, Payne K, et al. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess. 2011;15(33):1–102.
22. Curtis C, Shah S, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
23. NICE. NICE to assess high cost drugs for rare conditions. 2012. Available from http://www.nice.org.uk/newsroom/news/NICEToAssessHighCostDrugsForRareConditions.jsp.
24. EMA. Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products. 2011. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500121954.pdf.
25. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–43.